July Pages DOI: / Artrosis erosiva o inflamatoria: la gran desconocida. Erosive or inflammatory osteoarthritis: the great unknown. En las mujeres hay mayor prevalencia e incidencia de artrosis, tienden a tener La artrosis erosiva de manos es un subtipo de la artrosis de. Artrosis erosiva de las manos. Martínez Pardo et al. Semin Fund Esp. Reumatol ( ); 13(1) 5. Artrosis erosiva o inflamatoria: la gran desconocida.

Author: Fegar Arashikinos
Country: Senegal
Language: English (Spanish)
Genre: Finance
Published (Last): 19 May 2018
Pages: 264
PDF File Size: 4.29 Mb
ePub File Size: 5.31 Mb
ISBN: 287-3-45336-796-6
Downloads: 64617
Price: Free* [*Free Regsitration Required]
Uploader: Zulkigor

Clinical trials The European Union Clinical Trials Register allows you to search for protocol and results information on: Cancer AND drug name. Pneumonia AND sponsor name.

How to search [pdf]. For these items you should use the filters and not add them to your search terms in the text field. Trials with results Trials without results Clear advanced search filters. Review by the Competent Authority or Ethics Committee in the country concerned. EU Clinical Trials Register. Both Female Only Male Only.

IMP with orphan designation in the indication. Trials with results Trials without artrrosis. Clear advanced search filters. Date on which this record was first entered in the EudraCT database:. Title of the trial for lay people, in easily understood, i. Clinical trial where the treatment allocation is made randomly. Neither investigator nor artroiss will know which of the two possible treatments the patient is actually receiving.

The aim of the study is to assess the efficacy and safety of the combination of Chondroitin Sulphate and Glucosamine Hydrochloride in Patients with Hand Osteoarthritis. The IMP has been designated in this indication as an orphan drug in the Community.

Committee on Advanced therapies CAT has issued a classification for this product. Combination product that includes a device, but drosiva not involve an Advanced Therapy.

Prevalencia y síntomas de la artrosis | Dra. Elena Ruiz Domingo

Patients who have pain and deformities in at least 2 interphalangeal joints of the studied hand; 4. Patients with erosiba standard anteroposterior X-ray of both hands obtained within the 6 months prior to screening; 5.


Patients with radiological evidence of hand osteoarthritis grade according to the Kellgren-Lawrence radiological scale Patients must present ersiva involvement of at least 3 interphalangeal joints of the studied hand, with or without rhizarthrosis; 6. Patients who have had pain in the studied hand most of the days of the month prior to the screening visit; 7.

Patients with hand pain?

There was a problem providing the content you requested

Women of childbearing age women whose last menstrual period was more than one year before study enrolment and those who have had tubal ligation or a hysterectomy performed are excluded must have obtained a negative result for the pregnancy test conducted in the screening phase and must agree to use a medically acceptable contraceptive method throughout the duration of the study.

Men participating in the study must also agree to use a medically acceptable contraceptive if they have intercourse with women of childbearing age; Patients must have a sufficient level of cognition to allow for proper communication and cooperation with all tests and artorsis required in the protocol; Patients who have been clearly informed of the methods and limitations of the study and agree to sign the informed consent form prior to the conduct artrosid any study procedure and after they; Patients who are not participating in another clinical trial; Patients who agree to respect the protocol, attending visits related to the study.

Varones y mujeres con edad? Pacientes que acepten respetar el protocolo, acudiendo a las visitas relacionadas con el estudio. Patients with a known allergy to CS or GH; 3. Patients with a seafood allergy; 4. Patients with a history of intolerance to paracetamol; 5. Patients with active malignancy of any type or with a history of malignancy in the last five years; 6.

Patients who, in the investigator’s judgement, do not have significant clinical alterations in their physical examination and laboratory parameters; 7. History of any condition which, in the investigator’s opinion, could lead to misinterpretation of the study results or could pose an additional risk to the patient; 8.


Pain in other parts of the body more intense than in the hand, which could interfere xrtrosis the assessment of the artrozis index; Patients with fibromyalgia; Patients with surgery scheduled during the clinical trial period; Patients with important diseases or processes, such as psychological or psychiatric erosifa or drug consumption which, in the investigator’s opinion, is likely to alter the progress of the osteoarthritis or the patient’s ability to complete the study; Patients with poorly controlled hypertension sustained systolic blood pressure?

Patients with active acute or chronic infections that require antibiotic treatment, or serious fungal or viral infections for example, hepatitis, erossiva zoster, HIV positive ; Patients with a history of alcohol or drug consumption or abuse in the last 3 years; Patients who have received any investigationa drug in the 30 days prior to the secreening visit; Women who are breastfeeding; Patients who are receiving lithium carbonate, phenytoin or anti-coagulants, such as warfarin with the exception of ASA up to a maximum daily dose of mg.

Pacientes con alergia conocida al CS o el HG; 3. Pacientes con alergia al marisco; 4.

Pacientes con antecedentes de intolerancia al paracetamol; 5. Pacientes con fibromialgia; Mujeres en periodo de lactancia; Selection visit, day 0, 30, 60, y The trial involves single site in the Member State concerned. Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial.

Treatment period 6 months. El periodo de tratamiento es de 6 meses. Plans for treatment or care after the subject has ended the participation in the trial if it is different from the expected normal treatment of that condition.